SCHEMBL22765211

SCHEMBL22765211

CN(Cc1ccc2cccc(NS(=O)(=O)c3ccc(C(F)(F)F)cc3)c2n1)Cc1ccc2cccc(NS(=O)(=O)c3ccc(C(F)(F)F)cc3)c2n1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC40A1 Q9NP59 8/20 0.63
▸ GLO1 Q04760 3/20 0.51
▸ KMT2A Q03164 3/20 0.51
▸ MEN1 O00255 2/20 0.51
▸ TDP1 Q9NUW8 2/20 0.51
▸ HSD11B1 P28845 1/20 0.51
▸ AGTR1 P30556 2/20 0.49
▸ PAX8 Q06710 1/20 0.49
▸ NFKBIA P25963 1/20 0.48
▸ RELA Q04206 1/20 0.48
▸ LMNA P02545 2/20 0.46
▸ MAPT P10636 2/20 0.46
▸ HTT P42858 2/20 0.46
▸ PTGES2 Q9H7Z7 1/20 0.46
▸ MITF O75030 1/20 0.46
▸ S1PR4 O95977 1/20 0.46
▸ ALDH1A1 P00352 1/20 0.46
▸ S1PR1 P21453 1/20 0.46
▸ OPRK1 P41145 1/20 0.46
▸ CKS1B P61024 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26053882 0.96 KMT2A (0.58) SLC40A1GLO1KMT2AMEN1TDP1
SCHEMBL22765078 0.96 SLC40A1 (0.60) SLC40A1GLO1KMT2AMEN1TDP1
SCHEMBL22734222 0.94 SLC40A1 (0.61) SLC40A1GLO1KMT2AMEN1TDP1
Hydrochloric Acid SCHEMBL30471620 0.94 SLC40A1 (0.60) SLC40A1GLO1KMT2AMEN1TDP1
SCHEMBL26053979 0.93 SLC40A1 (0.59) SLC40A1GLO1KMT2AMEN1TDP1
SCHEMBL26053880 0.92 KMT2A (0.56) SLC40A1GLO1KMT2AMEN1TDP1
SCHEMBL22764963 0.90 SLC40A1 (0.59) SLC40A1GLO1KMT2AMEN1TDP1
SCHEMBL22764831 0.89 SLC40A1 (0.57) SLC40A1GLO1KMT2AMEN1TDP1
SCHEMBL22765051 0.87 SLC40A1 (0.63) SLC40A1GLO1KMT2AMEN1TDP1
SCHEMBL22765054 0.86 SLC40A1 (0.57) SLC40A1GLO1KMT2AMEN1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3728194-B1 QUINOLINE SULFONAMIDE COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS OTAGO INNOVATION LTD (NZ) 2025-06-04 — — EP disclosed
US-11691949-B2 Quinoline sulfonamide compounds and their use as antibacterial agents OTAGO INNOVATION LIMITED (NZ) 2023-07-04 — — US disclosed
US-11691949-B2 Quinoline sulfonamide compounds and their use as antibacterial agents OTAGO INNOVATION LIMITED (NZ) 2023-07-04 — — US disclosed
US-20200385354-A1 Quinoline Sulfonamide Compounds and Their Use as Antibacterial Agents OTAGO INNOVATION LIMITED (NZ) 2020-12-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11691949-B2 Quinoline sulfonamide compounds and their use as antibacterial agents NQO2, SDHA, SIRT5 SLC40A1 4081/4885GLO1 369/4885KMT2A 1680/4885
US-20200385354-A1 Quinoline Sulfonamide Compounds and Their Use as Antibacterial Agents NQO2, SDHA, SIRT5 SLC40A1 4081/4885GLO1 369/4885KMT2A 1680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback